Levosimendan Stada

Levosimendan, the active ingredient in Levosimendan Stada, is a calcium sensitizer presented as an intravenous formulation for intravenous use. It is employed in the management of acute decompensated heart failure to improve cardiac contractility and reduce symptoms in hospitalized patients.

GNH USA supplies Levosimendan Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and intensive‑care units worldwide.

Levosimendan is indicated for conditions affecting cardiac output and systemic perfusion.

Acute decompensated heart failure: improves cardiac output and relieves congestion. Low cardiac output syndrome: enhances myocardial contractility without increasing intracellular calcium. Post‑cardiac surgery ventricular dysfunction: supports hemodynamics during early postoperative period.

Levosimendan may be associated with several adverse reactions that clinicians monitor during therapy.

Common Side Effects: - Hypotension: drop in blood pressure, especially after rapid infusion. - Headache: mild to moderate intensity. - Nausea or vomiting: gastrointestinal discomfort. - Dizziness or light‑headedness. - Tachycardia: increased heart rate. - Peripheral edema: swelling of extremities.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Arrhythmias: ventricular or atrial ectopic beats. - Myocardial ischemia: chest pain or ECG changes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Pulmonary edema: worsening respiratory status. - Liver enzyme elevation: abnormal hepatic function tests.

Levosimendan requires careful patient assessment and monitoring before and during administration.

Cardiovascular monitoring: continuous blood pressure and heart‑rate observation is essential. Renal impairment: use with caution in severe renal dysfunction; dose adjustment may be needed. Hepatic impairment: consider reduced dosing in patients with significant liver disease. Concomitant vasodilators: may potentiate hypotensive effects; adjust therapy accordingly. Electrolyte disturbances: correct hypokalemia or hypomagnesemia before infusion. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with several drug classes, influencing its safety profile.

Major Interactions (Avoid): - Sodium nitroprusside: additive hypotensive effect. - Phosphodiesterase‑5 inhibitors: risk of severe blood‑pressure fall. - Other calcium sensitizers: unknown synergistic actions.

Moderate Interactions (Monitor Closely): - Loop diuretics: may alter intravascular volume status. - ACE inhibitors or ARBs: monitor for excessive hypotension. - Anticoagulants: observe for increased bleeding tendency.